Entering text into the input field will update the search result below

Viking Therapeutics: A Strong Grower To Service The Lucrative NASH Market


  • Viking is powering a highly promising pipeline of several potential big winners. VK2809 is quite similar to the strong nonalcoholic steatohepatitis ("NASH") molecule, MGL-3196 of Madrigal.
  • Upcoming Phase 2 data reporting of VK2809 for nonalcoholic fatty liver disease and hypercholesterolemia can spark another rally.
  • Other strong molecules to enable more "shots on goal" of finding a blockbuster.
  • Members of my private investing community, Integrated BioSci Investing, can follow this idea, as well as my other top picks with access to my model portfolio. Start your free trial today >>

You are neither right nor wrong because the crowd disagrees with you. You are right because your data and reasoning are right. - Benjamin Graham

Viking Therapeutics (NASDAQ:NASDAQ:VKTX) is a highly promising grower alerted to us by members of Integrated BioSci Investing. The stock enjoyed a similar strong rally subsequent to the robust Phase 2 outcomes of MGL-3196 of Madrigal Pharmaceuticals (MDGL) - a company featured in our Specialty Report that catapulted Madrigal's shares by +144% in one day. In our analysis of Viking, we noticed that the company is brewing a similar molecule to MGL-3196 that has substantial prospects. Notwithstanding, there are other interesting pipeline innovations that are overlooked. All that being said, we'll feature a fundamental analysis of the company while focusing on the upcoming clinical binary that can deliver much further upsides to this investment.

Figure 1: Viking stock chart. (Source: StockCharts)

Fundamental Analysis

Based in San Diego, CA, Viking Therapeutics is focused on the development and commercialization of novel medicines to service the metabolic and endocrine diseases. The company has the exclusive global rights to five drug franchises, which are powered by small molecules licensed from Ligand Pharmaceuticals (NASDAQ:LGND). It's seemingly that the crown jewel of the pipeline is VK2809 (Figure 2). As an agonist (i.e. activator) of the selective thyroid beta receptor, VK2809 is currently being assessed in a Phase 2 trial for the treatment of non-alcoholic fatty liver disease ("NAFLD") and high blood cholesterol (hypercholesterolemia). Despite that its most promising indication is in NAFLD (a spectrum of liver diseases that includes NASH), VK2809 is concurrently being investigated as a potential management for the orphan conditions - glycogen storage disease ("GSD") Type Ia and X-linked adrenoleukodystrophy ("X-ALD").

That aside, there is VK5211, an oral nonsteroidal selective androgen receptor modulator ("SARM"). In a Phase 2 trial that studied patients recovering

Author's Notes: We're honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing ("IBI") is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, Madrigal and Kite procured over 186%, 167%, 162%, 204%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advanced and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

This article was written by

BioSci Capital Partners profile picture
The #1 Biotech Service for Growth Investing and Catalyst Power Trading

As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading. 

Since inception, our flagship portfolio has delivered over 
31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.

Check out some of
our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.

In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis.
The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.

Follow us for the latest research. And,
take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!

Check out Dr. Harvey’s
LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Our research articles are best used as starting points in your own due diligence. We are not registered investment advisors and our articles are not construed as professional investment advice.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.